AI-generated · cited to primary sources · not investment advice
Bharat Electron (500049) May 2025 Filing Analysis
Does management do what it says?
Management expects to maintain a defense to non-defense revenue ratio of approximately 90:10. — target: 90:10
“And defense to nondefense business, typically we are expecting around 90:10 ratio.”
See the full cited Management analysis of Bharat Electron
How durable is the business?
EBITDA margins saw a significant jump to 29.39% due to increased scale of operations and higher indigenization. (1 expanding)
“The EBITDA also has increased to 29.39%, as compared to 25.22% last year.”
See the full cited Business Model analysis of Bharat Electron
Where does growth come from?
Non-defense revenue currently stands at 6-7%. Management is actively working to diversify, aiming to cross 10% immediately and 15% in the longer run, though defense remains the primary driver at 92-93%. (3 new trend, 2 steady across 5 signals)
“Nondefense presently, as I told is around 6%, 7%... our aim is without EVM also, we want to cross 10% immediately. And in longer run, it should cross 15%-plus in nondefense.”
See the full cited Future Growth analysis of Bharat Electron
What could break the thesis?
Management clarified that while system integration improves the top line, they maintain margins by ensuring they also provide the 'homegrown' sub-systems within those large projects. (1 easing)
“subsystems which are there... will make my top line reasonably okay, but definitely my bottom line is more -- better with subsystems.”
The risk of order slippage persists; while QRSAM (INR 30,000 Cr) is expected by March, management admits it may slip to Q1 of the next financial year due to procedural timelines. (1 stable, 1 easing, 1 intensifying)
“we are expecting QRSAM order, hopefully, before March, but it may slip to April, May also... worst case, it may be shifted by 1 quarter.”
See the full cited Risk analysis of Bharat Electron
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.